慢加急性肝衰竭免疫机制新视角

摘要/Abstract

摘要： 慢加急性肝衰竭(acute-on-chronic liver failure,ACLF)是一类在慢性肝病基础上发生的以急性肝功能失代偿、肝外器官损伤和短期高病死率为特征的严重临床综合征,其免疫机制复杂,尚未完全阐明。作者将从系统性炎症、免疫细胞相关损伤、线粒体功能障碍、转录组学和肠道微生物改变这五个方面介绍ACLF免疫机制相关的研究进展。

关键词: 慢加急性肝衰竭, 系统性炎症, 免疫细胞, 线粒体功能, 转录组学, 肠道微生物

李小慧, 张立婷, 李俊峰. 慢加急性肝衰竭免疫机制新视角[J]. 肝脏, 2025, 30(4): 426-430.

/ 推荐

[1] Monteiro S, Grandt J, Uschner F E, et al. Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation [J]. Gut, 2021, 70(2): 379-387.
[2] Hernaez R, Solà E, Moreau R, et al. Acute-on-chronic liver failure: an update [J]. Gut, 2017, 66(3): 541-553.
[3] Moreau R. The Pathogenesis of ACLF: The Inflammatory Response and Immune Function [J]. Semin Liver Dis, 2016, 36(2): 133-140.
[4] Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system [J]. Nat Immunol, 2015, 16(4): 343-353.
[5] Sharma A, Roy A, Premkumar M, et al. Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial [J]. Hepatol Int, 2022, 16(2): 433-446.
[6] Sundaram V, Jalan R, Ahn J C, et al. Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis [J]. J Hepatol, 2018, 69(3): 617-625.
[7] Ellulu M S, Patimah I, Khaza'Ai H, et al. Obesity and inflammation: the linking mechanism and the complications [J]. Arch Med Sci, 2017, 13(4): 851-863.
[8] Shaikh S R, Beck M A, Alwarawrah Y, et al. Emerging mechanisms of obesity-associated immune dysfunction [J]. Nat Rev Endocrinol, 2024, 20(3): 136-148.
[9] Lu X, Kong X, Wu H, et al. UBE2M-mediated neddylation of TRIM21 regulates obesity-induced inflammation and metabolic disorders [J]. Cell Metab, 2023, 35(8): 1390-405.e8.
[10] Acciarino A, Diwakarla S, Handreck J, et al. The role of the gastrointestinal barrier in obesity-associated systemic inflammation [J]. Obes Rev, 2024, 25(3): e13673.
[11] Wu W, Sun S, Wang Y, et al. Circulating Neutrophil Dysfunction in HBV-Related Acute-on-Chronic Liver Failure [J]. Front Immunol, 2021, 12(620365.
[12] Engelmann C, Sheikh M, Sharma S, et al. Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure [J]. J Hepatol, 2020, 73(1): 102-112.
[13] Zhang Y, Wu W, Wang Y, et al. Gene profiling of Toll-like receptor signalling pathways in neutrophils of patients with acute-on-chronic liver failure [J]. J Transl Med, 2021, 19(1): 465.
[14] Bernsmeier C, Triantafyllou E, Brenig R, et al. CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure [J]. Gut, 2018, 67(6): 1155-1167.
[15] Yao J, Liu T, Zhao Q, et al. Genetic landscape and immune mechanism of monocytes associated with the progression of acute-on-chronic liver failure [J]. Hepatol Int, 2023, 17(3): 676-88.
[16] Maheshwari D, Kumar D, Jagdish R K, et al. Bioenergetic Failure Drives Functional Exhaustion of Monocytes in Acute-on-Chronic Liver Failure [J]. Front Immunol, 2022, 13:856587.
[17] Peng B, Li H, Liu K, et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure [J]. J Transl Med, 2023, 21(1): 419.
[18] Trovato F M, Zia R, Napoli S, et al. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation [J]. Hepatology, 2021, 74(2): 907-925.
[19] Du B, Teng J, Yin R, et al. Increased Circulating T Follicular Helper Cells Induced via IL-12/21 in Patients With Acute on Chronic Hepatitis B Liver Failure [J]. Front Immunol, 2021, 12:641362.
[20] Yu X, Yang F, Shen Z, et al. BTLA contributes to acute-on-chronic liver failure infection and mortality through CD4(+) T-cell exhaustion [J]. Nat Commun, 2024, 15(1): 1835.
[21] Zhang Y, Zhang X, Han J, et al. Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure [J]. Hepatol Int, 2023, 17(4): 1000-1015.
[22] Zhou X, Li Y, Ji Y, et al. PD-1 Involvement in Peripheral Blood CD8(+) T Lymphocyte Dysfunction in Patients with Acute-on-chronic Liver Failure [J]. J Clin Transl Hepatol, 2021, 9(3): 283-290.
[23] Zhao Y, He W, Wang C, et al. Characterization of intrahepatic B cells in acute-on-chronic liver failure [J]. Front Immunol, 2022, 13:1041176.
[24] Li H J, Yang N, Mu X, et al. Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure [J]. Hepatol Int, 2022, 16(6): 1398-1411.
[25] Yang B, Sun F, Chen Y, et al. Mononuclear myeloid-derived suppressor cells expansion is associated with progression of liver failure in patients with acute decompensation of cirrhosis [J]. Int Immunopharmacol, 2023, 122:110581.
[26] Yu X, Sun J, Yang F, et al. Granulocytic myeloid-derived suppressor cells increase infection risk via the IDO/IL-10 pathway in patients with hepatitis B virus-related liver failure [J]. Front Immunol, 2022, 13:966514.
[27] Zhang Z, Zou Z S, Fu J L, et al. Severe dendritic cell perturbation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure [J]. J Hepatol, 2008, 49(3): 396-406.
[28] Zhang I W, Curto A, López-Vicario C, et al. Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure [J]. J Hepatol, 2022, 76(1): 93-106.
[29] Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF [J]. J Hepatol, 2020, 72(4): 688-701.
[30] Engelmann C, Clària J, Szabo G, et al. Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction [J]. J Hepatol, 2021, 75 Suppl 1(Suppl 1): S49-s66.
[31] Weiss E, Dela Peña-Ramirez C, Aguilar F, et al. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET) [J]. Gut, 2023, 72(8): 1581-1591.
[32] Yang L, Zhen L, Li Z, et al. Human liver tissue transcriptomics revealed immunometabolic disturbances and related biomarkers in hepatitis B virus-related acute-on-chronic liver failure [J]. Front Microbiol, 2022, 13:1080484.
[33] Li J, Liang X, Jiang J, et al. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF [J]. Gut, 2022, 71(1): 163:175.
[34] Hassan H M, Cai Q, Liang X, et al. Transcriptomics reveals immune-metabolism disorder in acute-on-chronic liver failure in rats [J]. Life Sci Alliance, 2022, 5(3): e202101189.
[35] Liang X, Li P, Jiang J, et al. Transcriptomics unveils immune metabolic disruption and a novel biomarker of mortality in patients with HBV-related acute-on-chronic liver failure [J]. JHEP Rep, 2023, 5(9): 100848.
[36] Trebicka J, Bork P, Krag A, et al. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure [J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 167-180.
[37] Tranah T H, Edwards L A, Schnabl B, et al. Targeting the gut-liver-immune axis to treat cirrhosis [J]. Gut, 2021, 70(5): 982-994.
[38] Solé C, Guilly S, Da Silva K, et al. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis [J]. Gastroenterology, 2021, 160(1): 206-18.e13.
[39] Yao X, Yu H, Fan G, et al. Impact of the Gut Microbiome on the Progression of Hepatitis B Virus Related Acute-on-Chronic Liver Failure [J]. Front Cell Infect Microbiol, 2021, 11:573923.
[40] Wang K, Zhang Z, Mo Z S, et al. Gut microbiota as prognosis markers for patients with HBV-related acute-on-chronic liver failure [J]. Gut Microbes, 2021, 13(1): 1-15.
[41] Odenwald M A, Lin H, Lehmann C, et al. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease [J]. Nat Microbiol, 2023, 8(11): 2033-2049.

慢加急性肝衰竭免疫机制新视角

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	许景, 杨永峰. 慢加急性肝衰竭患者90 d预后模型的构建[J]. 肝脏, 2025, 30(4): 532-536.
[2]	王炳鸿, 徐彤彤, 马雄, 王绮夏. 自身免疫性肝病相关微生物研究进展[J]. 肝脏, 2025, 30(2): 151-155.
[3]	王炳鸿, 王绮夏, 肖潇. 免疫细胞在原发性硬化性胆管炎进程中的研究进展[J]. 肝脏, 2025, 30(1): 10-13.
[4]	邓茹心, 雷思贤, 孟忠吉. 糖皮质激素改善慢加急性肝衰竭前期及早期患者结局[J]. 肝脏, 2025, 30(1): 31-36.
[5]	钟良辉, 周定英, 毛雅倩, 钟渊斌. 慢加急性肝衰竭预后评估进展[J]. 肝脏, 2025, 30(1): 128-131.
[6]	秦慧敏, 王晓霖. 误诊为白血病的酒精性肝病相关肝衰竭合并白细胞升高1例[J]. 肝脏, 2025, 30(1): 143-145.
[7]	董旭, 廖威, 许明晓, 葛玲玲, 陈怡, 李成忠. HBV相关慢加急性肝衰竭患者低血糖的危险因素及与临床转归的关系[J]. 肝脏, 2024, 29(9): 1117-1122.
[8]	陈然, 王帅, 高扬, 杨志琴, 徐严. HBV相关慢加急性肝衰竭合并脓毒症的诊疗进展[J]. 肝脏, 2024, 29(7): 867-870.
[9]	韩肇丹, 许军, 李芃芃, 赵卫娟. AARC-ACLF评分联合NLR对HBV相关慢加急性肝衰竭短期预后的评估价值[J]. 肝脏, 2024, 29(5): 538-541.
[10]	周晓丽, 魏丽, 王兆勋, 杨学芳, 施文娟, 万红. TBRR、TBCR对人工肝治疗HBV相关慢加急性肝衰竭患者预后的评估价值[J]. 肝脏, 2024, 29(5): 542-544.
[11]	郭庆鑫, 姚婷, 沈乐而, 陈金梅, 胡微微, 张毅, 陈小华. IRS-2通过PI3K/AKT通路调控肝细胞焦亡的实验研究[J]. 肝脏, 2024, 29(5): 561-566.
[12]	陈治莉, 谢青, 莫瑞东. TIPS在慢加急性肝衰竭静脉曲张再出血高风险人群中的应用和评价[J]. 肝脏, 2024, 29(5): 596-599.
[13]	王小燕, 张雨夜, 田李均, 韩旭东. 固有免疫细胞在急性肝衰竭发生和发展中的作用及研究进展[J]. 肝脏, 2024, 29(3): 358-362.
[14]	秦慧敏, 王晓霖. HBV相关慢加急性肝衰竭短期预后预测模型构建及验证[J]. 肝脏, 2024, 29(12): 1521-1526.
[15]	林建辉, 陈丽霞, 翁钘钘, 陈敏, 谢文国, 刘海钰. 选择性血浆置换术前血小板水平与HBV相关慢加急性肝衰竭患者院内预后的关联[J]. 肝脏, 2024, 29(12): 1527-1533.